WO2005027843A3 - Chronotherapeutic dosage forms - Google Patents

Chronotherapeutic dosage forms Download PDF

Info

Publication number
WO2005027843A3
WO2005027843A3 PCT/US2004/030456 US2004030456W WO2005027843A3 WO 2005027843 A3 WO2005027843 A3 WO 2005027843A3 US 2004030456 W US2004030456 W US 2004030456W WO 2005027843 A3 WO2005027843 A3 WO 2005027843A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage forms
chronotherapeutic
chronotherapeutic dosage
core
surfactant
Prior art date
Application number
PCT/US2004/030456
Other languages
French (fr)
Other versions
WO2005027843A2 (en
Inventor
Anand R Baichwal
Paul Woodcock
Steve Labudzinski
Original Assignee
Penwest Pharmaceuticals Co
Anand R Baichwal
Paul Woodcock
Steve Labudzinski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penwest Pharmaceuticals Co, Anand R Baichwal, Paul Woodcock, Steve Labudzinski filed Critical Penwest Pharmaceuticals Co
Priority to MXPA06003101A priority Critical patent/MXPA06003101A/en
Priority to CA002539182A priority patent/CA2539182A1/en
Priority to AU2004273958A priority patent/AU2004273958A1/en
Priority to EP04784345A priority patent/EP1663156A2/en
Priority to JP2006527049A priority patent/JP2007519608A/en
Publication of WO2005027843A2 publication Critical patent/WO2005027843A2/en
Publication of WO2005027843A3 publication Critical patent/WO2005027843A3/en
Priority to IL174342A priority patent/IL174342A0/en
Priority to AU2008229834A priority patent/AU2008229834A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a surfactant and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core.
PCT/US2004/030456 2003-09-19 2004-09-17 Chronotherapeutic dosage forms WO2005027843A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MXPA06003101A MXPA06003101A (en) 2003-09-19 2004-09-17 Chronotherapeutic dosage forms.
CA002539182A CA2539182A1 (en) 2003-09-19 2004-09-17 Chronotherapeutic dosage forms
AU2004273958A AU2004273958A1 (en) 2003-09-19 2004-09-17 Chronotherapeutic dosage forms
EP04784345A EP1663156A2 (en) 2003-09-19 2004-09-17 Chronotherapeutic dosage forms
JP2006527049A JP2007519608A (en) 2003-09-19 2004-09-17 Time treatment dosage form
IL174342A IL174342A0 (en) 2003-09-19 2006-03-16 Chronotherapeutic dosage forms
AU2008229834A AU2008229834A1 (en) 2003-09-19 2008-10-09 Chronotherapeutic Dosage Forms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50403703P 2003-09-19 2003-09-19
US60/504,037 2003-09-19

Publications (2)

Publication Number Publication Date
WO2005027843A2 WO2005027843A2 (en) 2005-03-31
WO2005027843A3 true WO2005027843A3 (en) 2006-03-02

Family

ID=34375439

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/030456 WO2005027843A2 (en) 2003-09-19 2004-09-17 Chronotherapeutic dosage forms

Country Status (8)

Country Link
US (2) US20050118267A1 (en)
EP (1) EP1663156A2 (en)
JP (1) JP2007519608A (en)
AU (2) AU2004273958A1 (en)
CA (1) CA2539182A1 (en)
IL (1) IL174342A0 (en)
MX (1) MXPA06003101A (en)
WO (1) WO2005027843A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
KR101192722B1 (en) 2003-04-24 2012-10-18 자고텍 아게 Delayed release tablet with defined core geometry
EP1765292B1 (en) 2004-06-12 2017-10-04 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
DE102004043863A1 (en) * 2004-09-10 2006-03-16 Nitec Pharma Ag Tablets with local and time-controlled drug release in the gastrointestinal tract
MX2009001248A (en) 2006-08-03 2009-02-11 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease.
WO2008079868A1 (en) * 2006-12-22 2008-07-03 Drugtech Corporation Clonidine composition and method of use
ITFI20070253A1 (en) * 2007-11-09 2009-05-10 Valpharma Internat S P A PHARMACEUTICAL FORMULATIONS FOR THE ADMINISTRATION OF IPP.
EP2299986A1 (en) * 2008-06-19 2011-03-30 University Of The Witwatersrand, Johannesburg A chronotherapeutic pharmaceutical dosage form
WO2011069010A2 (en) 2009-12-02 2011-06-09 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
RU2587570C2 (en) 2010-04-14 2016-06-20 Алтрия Клаинт Сервисиз Инк. Moulded smokeless tobacco product
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
CA2991217C (en) 2010-12-22 2020-06-09 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
JP5638151B2 (en) 2010-12-23 2014-12-10 パーデュー、ファーマ、リミテッド、パートナーシップ Tamper resistant solid oral dosage form
JP5976657B2 (en) 2011-09-30 2016-08-24 持田製薬株式会社 Easy-to-use solid preparation
BR112015017451B1 (en) 2013-02-05 2023-01-10 Purdue Pharma L.P. TAMPER-RESISTANT PHARMACEUTICAL FORMULATIONS
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10799548B2 (en) 2013-03-15 2020-10-13 Altria Client Services Llc Modifying taste and sensory irritation of smokeless tobacco and non-tobacco products
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
IL272834B1 (en) 2017-08-24 2024-04-01 Adamas Pharma Llc Amantadine compositions, preparations thereof, and methods of use
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958456A (en) * 1993-09-09 1999-09-28 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US6372255B1 (en) * 1997-12-23 2002-04-16 Merck Patent Gesellschaft Tablet for instant and prolonged release of one or more active substances
WO2002072033A2 (en) * 2001-03-13 2002-09-19 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms containing glucocorticosteroid

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3131123A (en) * 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
US3148124A (en) * 1962-06-12 1964-09-08 William E Gaunt Method of preparing sustained release pharmaceutical tablets
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
FR2471186A1 (en) * 1979-12-10 1981-06-19 Roussel Uclaf NEW COLIC DELITESCENCE TABLETS AND THEIR PREPARATION PROCESS
US4851231A (en) * 1982-12-13 1989-07-25 Alza Corporation System for delivering drug in selected environment of use
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
SE457505B (en) * 1984-01-10 1989-01-09 Lejus Medical Ab LAMINATED ORAL PHARMACEUTICAL COMPOSITION AND PROCEDURES FOR ITS PREPARATION
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4853249A (en) * 1985-11-15 1989-08-01 Taisho Pharmaceutical Co., Ltd. Method of preparing sustained-release pharmaceutical/preparation
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
JPS62195323A (en) * 1986-02-24 1987-08-28 Eisai Co Ltd Gastric resident particle
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
IT1204294B (en) * 1986-03-11 1989-03-01 Gentili Ist Spa METHOD OF MANUFACTURE OF GRANULARS SUITABLE FOR THE PRODUCTION OF COATED TABLETS, FOR ORAL USE, WITH CONTROLLED RELEASE
US5238686A (en) * 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4842867A (en) * 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
GB8702411D0 (en) * 1987-02-03 1987-03-11 Zyma Sa Swellable pellets
NO883326L (en) * 1987-08-11 1989-02-13 Bayer Ag DHP-retard-COOK.
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US4841231A (en) * 1987-10-30 1989-06-20 Unisys Corporation Test probe accessibility method and tool
US4971805A (en) * 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same
JPH0768125B2 (en) * 1988-05-18 1995-07-26 エーザイ株式会社 Oral formulation of acid labile compounds
US4857337A (en) * 1988-05-24 1989-08-15 American Home Products Corp. (Del) Enteric coated aspirin tablets
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5334372A (en) * 1988-10-07 1994-08-02 Kao Corporation Alcohol-modified silicon ester derivative and cosmetic composition containing same
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5198227A (en) * 1990-01-22 1993-03-30 Mcneil-Ppc, Inc. Dual subcoated simulated capsule medicament
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
IT1241417B (en) * 1990-03-06 1994-01-14 Vectorpharma Int THERAPEUTIC COMPOSITIONS WITH CONTROLLED RELEASE OF DRUGS SUPPORTED ON CROSS-LINKED POLYMERS AND COATED WITH POLYMER FILM, AND THEIR PREPARATION PROCESS
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
JP2773959B2 (en) * 1990-07-10 1998-07-09 信越化学工業株式会社 Colon release solid preparation
US5202338A (en) * 1990-10-31 1993-04-13 Vilmos Bar Dihydroquinoline derivatives, pharmaceutical compositions and methods of use of dihydroquinoline derivatives as modulators of the arachidonic acid cascade
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
IT1251153B (en) 1991-08-06 1995-05-04 Vectorpharma Int SOLID PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION HAVING PROHIBITED GASTRIC RESIDENCE
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5262172A (en) * 1992-06-19 1993-11-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing buffered bile acids
US5302400A (en) * 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5330761A (en) * 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5395626A (en) * 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5399362A (en) * 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5713852A (en) * 1995-06-07 1998-02-03 Alza Corporation Oral dosage and method for treating painful conditions of the oral cavity
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
CA2231195C (en) * 1996-07-08 2003-01-21 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
DE19709532A1 (en) 1997-03-10 1998-09-17 Basf Ag Use of redispersible polymer powders or polymer granules for coating pharmaceutical or agrochemical dosage forms
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US5958873A (en) * 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
IN186245B (en) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
CN100444830C (en) * 1998-11-02 2008-12-24 伊兰公司，Plc Multiparticulate modified release composition
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958456A (en) * 1993-09-09 1999-09-28 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US6372255B1 (en) * 1997-12-23 2002-04-16 Merck Patent Gesellschaft Tablet for instant and prolonged release of one or more active substances
WO2002072033A2 (en) * 2001-03-13 2002-09-19 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms containing glucocorticosteroid

Also Published As

Publication number Publication date
EP1663156A2 (en) 2006-06-07
MXPA06003101A (en) 2006-06-20
CA2539182A1 (en) 2005-03-31
JP2007519608A (en) 2007-07-19
WO2005027843A2 (en) 2005-03-31
US9278076B2 (en) 2016-03-08
US20050118267A1 (en) 2005-06-02
US20090169587A1 (en) 2009-07-02
IL174342A0 (en) 2006-08-01
AU2008229834A1 (en) 2008-11-06
AU2004273958A1 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
WO2002072034A3 (en) Chronotherapeutic dosage forms
WO2005027843A3 (en) Chronotherapeutic dosage forms
WO2006124366A3 (en) Flavoring of drug-containing chewing gums
WO2005048923A3 (en) Extended release venlafaxine formulation
AU2003274680A1 (en) Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent
WO2005009381A3 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
AU5680100A (en) Controlled release and taste masking oral pharmaceutical compositions
AU2002349001B2 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
AU2002349001A1 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
MXPA02000277A (en) Texture masked particles containing an active ingredient.
WO2005021022A3 (en) Stable formulations of peptides
CA2396145A1 (en) Osmotic device containing pseudoephedrine and an h1 antagonist
EA200600598A1 (en) DOSAGE FORMS OF SLOW-DROP
WO2004108067A3 (en) Programmed drug delivery system
WO2007056073A3 (en) Medical device with a coating comprising an active form and an inactive form of therapeutic agent(s)
AU2002254036A1 (en) Taste masked pharmaceutical compositions
WO2002066002A3 (en) Pharmaceutical formulation
WO2001082875A3 (en) A core formulation
WO2004069135A3 (en) Composition comprising a mixture of active principles, and method of preparation
IL156623A0 (en) New film coating
WO2004108082A3 (en) Controlled release formulations
EP1238662A3 (en) Method for manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules
WO2004028504A8 (en) Modified release dosage forms
WO2005009410A3 (en) Pharmaceutical compositions having a swellable coating
WO2005039481A3 (en) Oral drug delivery system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004273958

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1403/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004784345

Country of ref document: EP

Ref document number: 2539182

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 174342

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/003101

Country of ref document: MX

Ref document number: 2006527049

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004273958

Country of ref document: AU

Date of ref document: 20040917

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004273958

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004784345

Country of ref document: EP